Advertisement

Topics

STAT Plus: Here’s why investors in Geron, Puma Bio, Intrexon, and Ziopharm should worry

04:30 EST 13 Nov 2017 | STAT

Columnist Adam Feuerstein pores over SEC filings and quarterly earnings reports and sees red flags ahead for Geron, Puma Bio, Intrexon, and Ziopharm.

Original Article: STAT Plus: Here’s why investors in Geron, Puma Bio, Intrexon, and Ziopharm should worry

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Here’s why investors in Geron, Puma Bio, Intrexon, and Ziopharm should worry"

Advertisement
Quick Search
Advertisement
Advertisement